OXFORD, England, July 18, 2011 /PRNewswire/ — In October 2007, Enigma Diagnostics (Porton Down, UK & San Diego, USA) announced the award of a euro 3 Million grant by the European Commission Framework 7 programme. This EU Commission award was won in a competitive process and the grant was to support development of a rapid, fully automated molecular diagnostic system for Seasonal Influenza (circulating strains of Influenza types A & B) to be based on Enigma’s concept ML (mini-laboratory) instrument system. The RANGER project started on 1st of July 2008 with a consortium of members. This was led by Enigma Diagnostics and included the UK Health Protection Agency (HPA) with responsibility for assay development, Sagentia (Harston, Cambridge, UK) supporting development of the EnigmaÃ‚® ML prototype system and Queen Sirikit National Institute of Child Health collecting samples for clinical trials. PERA administered the project on behalf of the consortium.
The concluding meeting of the RANGER consortium was held at Enigma’s Oxford site on 30th June 2011 at which Enigma demonstrated the use of the EnigmaÃ‚® ML system from sample to result in less than 60 minutes, using a swab and running a Seasonal Influenza, real-time PCR assay.
John McKinley, Chairman of Enigma Diagnostics, said, “Enigma and all of the RANGER consortium recognise the valuable contribution of the EU Commission in supporting the successful development of the EnigmaÃ‚® ML system. This has progressed from initial design concept to pre-clinical assessment of the Seasonal Influenza test at the HPA Porton Down laboratories earlier this year. The EnigmaÃ‚® ML system will now move to the commercialization stage during 2012.”
The EnigmaÃ‚® ML system will be showcased at AACC (American Association for Clinical Chemistry) at stand116 from 26th to 28th July 2011.
The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 201569.
About Enigma Diagnostics Limited
Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Enigma’s innovative and proprietary technologies combine the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma’s commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.
For more information visit www.enigmadiagnostics.com
Telephone: + 44 (0)1235 854076
SOURCE Enigma Diagnostics Limited